Contact Us
Drug Search Results
More Filters [+]

SHP-639

Alternative Names: shp-639, shp639, shp 639
Latest Update: 2019-08-07
Latest Update Note: Clinical Trial Update

Product Description

TAK-639 is a topical, nine-amino acid, synthetic, C-type natriuretic peptide analog in Phase 1 development for the treatment of ocular hypertension (OHT) and primary open-angle glaucoma (POAG). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32256046/)

Mechanisms of Action: NPRB Agonist

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SHP-639

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Hypertension|Glaucoma, Open-Angle

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SHP639-101

P1

Completed

Glaucoma, Open-Angle|Hypertension

2018-05-30

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions